A Phase 1, Dose Escalation Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom no Standard Therapy is Available

Trial Profile

A Phase 1, Dose Escalation Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom no Standard Therapy is Available

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Margetuximab (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Oesophageal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 22 Mar 2017 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.
    • 22 Mar 2017 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.
    • 22 Mar 2017 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top